Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment

Sponsor
Novartis Pharmaceuticals
Study ID
NCT04632927
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Secukinumab — BIOLOGICAL
    Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
  • Ustekinumab — BIOLOGICAL
    Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio

Study Details

The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment

Key Dates

Start date
Dec 21, 2020
Status verified
Sep 2025
Primary completion
Oct 22, 2024
Completion
Oct 22, 2024

Study Design

Enrollment
119 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Secukinumab
    AIN457
  • Experimental: Ustekinumab

Primary Outcome Measure

Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 [ Time Frame: Baseline, Week 28 ]

Related coverage on Hipa.ai

Related Studies